Metabolism Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

HPS2-THRIVE study: Tredaptive did not achieve primary endpoint

Merck ( MSD ) has announced that the HPS2-THRIVE ( Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events ) study of Tredaptive ( extended-release Niacin / Laropiprant ) did not meet its primary endpoint.
The company is also preparing communications to health care providers in countries where the medicine is currently available, and will continue to work with regulators to provide updated information to health care providers. Based on the current understanding of these new data and until further analyses can be completed, Merck is recommending that providers not start new patients on Tredaptive. Merck does not plan to seek regulatory approval for the medicine in the United States.

HPS2-THRIVE was independently conducted by the Clinical Trial Service Unit at Oxford University and funded by Merck. The study enrolled 25,673 patients considered to be at high risk for cardiovascular events. Of those enrolled, 14,741 were from Europe ( United Kingdom and Scandinavia ) and 10,932 were from China.
Patients in the study were followed for a median of 3.9 years. HPS2-THRIVE compared extended -release Niacin and Laropiprant plus statin therapy versus statin therapy. It was not designed to assess directly the separate effects of either extended-release Niacin or Laropiprant.

In the study, adding the combination of extended-release Niacin and Laropiprant to statin therapy did not significantly further reduce the risk of the combination of coronary deaths, non-fatal heart attacks, strokes or revascularizations compared to statin therapy. In addition, there was a statistically significant increase in the incidence of some types of non-fatal serious adverse events in the group that received extended-release Niacin / Laropiprant.

With the agreement of the independent research team at Oxford University, Merck is sharing results from the study with regulatory agencies in countries where the medicine is approved ( under the brand names Tredaptive or Cordaptive ) and in other countries as well. The investigators are conducting additional analyses, including regional analyses, to further understand the results. They anticipate reporting the detailed study results in the first quarter of 2013.

Tredaptive / Cordaptive has been approved in approximately 70 countries, including in Europe, and is sold in approximately 40 countries. Tredaptive is also sold under the brand names Pelzont in Italy and Trevaclyn in Italy and Portugal. ( Xagena )

Fonte: Merck, 2012